Tumor immunotherapy works by stimulating the host's immune system to generate a systemic immune response against the spread of tumor cells.[1] Among various immunotherapies, ICB therapy based on the PD‐1/PD‐L1 pathway has made important clinical advances. This evidence concerns the gene CD274 and neoplasm.